Case 1:07-cv-00331-SLR
Document 50
Filed 03/27/2008
Page 1 of 10
IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE TAKEDA PHARMACEUTICAL COMPANY LIMITED, TAP PHARMACEUTICAL PRODUCTS INC., and ETHYPHARM, S.A, Plaintiffs, v. TEVA PHARMACEUTICALS USA, INC., and TEVA PHARMACEUTICAL INDUSTRIES LTD., Defendants. ) ) ) ) ) ) ) ) ) ) ) )
C.A. No. 07-331 (SLR)
PLAINTIFFS' NOTICE OF DEPOSITION PURSUANT TO FED. R. CIV. P. 30(b)(6) TO TEVA PHARMACEUTICALS USA, INC. To: Ann G. Fort, Esquire SUTHERLAND, ASBILL & BRENNAN LLP 999 Peachtree Street, NE Atlanta, GA 30309-3996 PLEASE TAKE NOTICE that, in accordance with Rules 26 and 30(b)(6) of the Federal Rules of Civil Procedure, Plaintiffs Takeda Pharmaceutical Company, Ltd. ("Takeda"), TAP Pharmaceutical Products Inc. ("TAP"), and Ethypharm, S.A. ("Ethypharm"), by and through their attorneys, will take the deposition of Defendant Teva Pharmaceuticals USA, Inc. ("Teva") through one or more of its officers, directors, managing agents, or other persons who consent to testify on its behalf and who are most knowledgeable with respect to the deposition subjects set forth in Schedule A at the time and place set forth below. Said deposition will be taken on May 7, 2008 at 9:30 a.m. and will be taken at the offices of Baker Botts L.L.P., 30 Rockefeller Plaza, New York, NY, or at such other time and place as may be agreed to by the parties. The deposition will continue day-to-day until
Case 1:07-cv-00331-SLR
Document 50
Filed 03/27/2008
Page 2 of 10
completed as provided in the Federal Rules of Civil Procedure and the Discovery Order in this case. The deposition will be recorded stenographically and by videotape. PLEASE TAKE FURTHER NOTICE that Teva is requested to identify, on or before May 1, 2008, its designated witnesses, their full titles and the matters to which each will testify. You are invited to attend and cross-examine. MORRIS, NICHOLS, ARSHT & TUNNELL LLP
/s/ James W. Parrett, Jr.
__________________________________ Jack B. Blumenfeld (#1014) Mary B. Graham (#2256) Rodger D. Smith II (#3778) James W. Parrett, Jr. (#4292) 1201 N. Market Street P.O. Box 1347 Wilmington, DE 19801 [email protected] 302.658.9200
OF COUNSEL: Eric J. Lobenfeld Tedd W. Van Buskirk Arlene L. Chow Dillon Kim HOGAN & HARTSON LLP 875 Third Avenue New York, New York 10022 212.918.3000 Philippe Y. Riesen HOGAN & HARTSON LLP Shinjuku Center Building, 46th Floor 25-1 Nishi-Shinjuku 1-chome Shinjuku, Tokyo 163-0646 Japan (81) 3-5908-4070 Richard de Bodo HOGAN & HARTSON LLP 1999 Avenue of the Stars, Suite 1400 Los Angeles, CA 90067 310.785.4600 Attorneys for Takeda Pharmaceutical Company Limited
Attorneys for Takeda Pharmaceutical Company Ltd., TAP Pharmaceutical Products Inc., and Ethypharm, S.A,
-2-
Case 1:07-cv-00331-SLR
Document 50
Filed 03/27/2008
Page 3 of 10
William F. Cavanaugh Stuart E. Pollack Melissa Mandrgoc Patrick S. Almonrode PATTERSON BELKNAP WEBB & TYLER LLP 1133 Avenue of the Americas New York, New York 10036 212.336.2000 Attorneys for TAP Pharmaceutical Products Inc. Paul A. Ragusa Lisa B. Kole Sandra S. Lee BAKER BOTTS LLP 30 Rockefeller Plaza New York, NY 10112-4498 212.408.2500 Attorneys for Ethypharm, S.A. March 27, 2008
2170543
-3-
Case 1:07-cv-00331-SLR
Document 50
Filed 03/27/2008
Page 4 of 10
SCHEDULE A DEFINITIONS A. "Teva" means Defendant Teva Pharmaceuticals USA, Inc.; all parents,
subsidiaries, and affiliates thereof; all divisions, predecessors, successors, and assigns of each of the foregoing; and all officers, directors, employees, agents, consultants, attorneys, and all other persons acting or purporting to act on behalf of, or under the control of, each of the foregoing. B. The "Patents-in-Suit" shall mean, for purposes of this Notice, U.S. Patent
Nos. 5,464,632 ("the `632 patent"), and 6,328,994 ("the `994 patent"). C. The term "ANDA" means an Abbreviated New Drug Application filed
with the Food and Drug Administration ("FDA"). D. E. The term "ODT" means orally-disintegrating tablet. The term "Teva's ODT Products" mean the pharmaceutical forms which
are the subject of Teva's ANDA No. 78-730. F. "Concerning" means comprising, containing, embodying, discussing,
reflecting, identifying, referring to, relating to, describing, evidencing, or constituting. G. The term "communication" means the transfer or transmittal of
information (in the form of facts, ideas, inquiries, or otherwise), whether oral or written. H. "Person" shall mean (a) natural persons (also referred to as "individuals"),
(b) legal entities, including, without limitation, corporations, partnerships, firms, associations, professional corporations and proprietorships, and (c) governmental bodies or agencies. I. to state: To "identify" or provide "identification" in the case of a document means
Case 1:07-cv-00331-SLR
Document 50
Filed 03/27/2008
Page 5 of 10
i. ii.
The document's title and date, if any, as well as a brief description of its subject matter; The type or nature of the document (e.g., letter, memorandum, telegram, chart, laboratory report, etc.) and the number of pages in it; The identity of any person who prepared the document (and, if different, the identity of any person who signed the document); The date the document was drafted; The identity of any person who received a copy of the document (whether an addressee or otherwise); The present whereabouts of the document and the identity of its custodian; and All other means of identifying the document with sufficient particularity to support a request for production under Rule 34 of the Federal Rules of Civil Procedure.
iii. iv. v. vi. vii.
J. state:
To "identify" or provide "identification" in the case of a thing means to
i.
A brief description of the thing, including any product numbers, part numbers, model numbers, catalog numbers, style numbers, code numbers, brand names, trade names, trademarks, commercial or governmental designations, and any other identifying markings, features, or characteristics; The present whereabouts of the thing; The identity of the person having possession, custody, or control of the thing; and All other means of identifying the thing with sufficient particularity to support a request for production under Rule 34 of the Federal Rules of Civil Procedure.
ii. iii. iv.
K. state:
To "identify" or provide "identification" in the case of a person means to
i. ii.
The person's home and business addresses (present or last known); The person's full name; and
-2-
Case 1:07-cv-00331-SLR
Document 50
Filed 03/27/2008
Page 6 of 10
iii. L.
The time period and nature of each of his or her present and prior employment positions or affiliations with Teva, if any.
To "identify" or provide "identification" in the case of a department,
affiliate or group means to state: i. ii. iii. iv. M. The full name of the department, affiliate or group; The nature of the department, affiliate or group and its corporate relationship to or within Teva; The location of its offices; and The identity of each of its principals, officers, directors, partners, or members.
"And" and "or" shall be construed conjunctively or disjunctively as
necessary to make the discovery requests inclusive rather than exclusive; use of a singular noun shall be construed to include the plural noun, and use of a plural noun shall be construed to include the singular noun; the use of a verb in any tense shall be construed as the use of that verb in all other tenses whenever necessary to bring within the scope of the discovery request documents or information that might otherwise be construed to be outside its scope. RULE 30(b)(6) TOPICS 1. The identity and corporate organizational/reporting structure of the
departments, affiliates, groups, and individuals involved in the research, formulation, testing, government approval, development, manufacture, distribution, sale, marketing or licensing of Teva's ODT Products. 2. The circumstances under which Teva decided to begin formulating or
developing Teva's ODT Products, including but not limited to a description of the technical and marketing reasons for such development.
-3-
Case 1:07-cv-00331-SLR
Document 50
Filed 03/27/2008
Page 7 of 10
3.
The research, evaluation, studies, testing, calculations, analyses, statistical
interpretation, validation of stability studies, formulation development reports, and any other communication or information related to the development and features of Teva's ODT Products and any lansoprazole orally-dissolving tablet formulation considered by Teva, including but not limited to any formulation abandoned, contemplated, discussed, or proposed by or for Teva. 4. The facts and circumstances concerning the preparation, submission, and
review of ANDA No. 78-730. 5. The development, scale-up, commercial manufacture and testing of Teva's
ODT Products, including but not limited to, bioequivalence testing, dissolution testing, stability studies, in vivo and in vitro tests, and test results and conclusions. 6. Any actual or contemplated modifications to the manufacturing process
set forth in ANDA No. 78-730. 7. 8. Any amendments, supplements, or modifications to ANDA No. 78-730. Any deficiency notices or letters from the Food and Drug Administration
regarding ANDA No. 78-730. 9. The facts and circumstances concerning the preparation and service of
Teva's April 12, 2007 Notice Letter, including but not limited to the identification of all facts, documents, data, studies, investigations, opinions, and analyses that were considered in preparing the Notice Letter. 10. The factual bases for Teva's contentions or beliefs that Teva's ODT
Products have not infringed, are not infringing and will not infringe, either literally or under the doctrine of equivalents, any valid and enforceable claim of the Patents-in-Suit, including but not
-4-
Case 1:07-cv-00331-SLR
Document 50
Filed 03/27/2008
Page 8 of 10
limited to the identification of all facts, documents, data, studies, investigation, opinions, and analyses that support Teva's contentions or beliefs. 11. The factual bases for Teva's contentions or beliefs that the claims of the
Patents-in-Suit are invalid and/or unenforceable for failure to comply with the requirements of the patent laws of the United States, including without limitation 35 U.S.C. §§ 101, 102, 103, and/or 112, including but not limited to the identification of all facts, documents, data, studies, investigation, opinions, and analyses that support Teva's contentions or beliefs. 12. The date upon and circumstances under which Teva first learned of the
existence of each of the Patents-in-Suit. 13. The facts and circumstances concerning any efforts by Teva to monitor the
prosecution of any of the Patents-in-Suit, related applications to the Patents-in-Suit, and/or foreign counterpart applications to the Patents-in-Suit. 14. The facts and circumstances concerning any due diligence or other efforts
undertaken by Teva concerning the validity and/or enforceability of any of the Patents-in-Suit, related applications to the Patents-in-Suit, and/or foreign counterpart applications to the Patentsin-Suit. 15. Teva's patent application(s), whether filed in the U.S. under the Patent
Cooperation Treaty, or in any country, relating to any lansoprazole ODT products. 16. Teva's strategies, expectations, and results for the marketing of Teva's
ODT Products, and the development of training materials, marketing materials, product road maps, and promotional efforts for Teva's ODT Products. 17. All facts concerning the importance or impact of Teva's use of the
Patents-in-Suit in the marketing and sales of Teva's ODT Products.
-5-
Case 1:07-cv-00331-SLR
Document 50
Filed 03/27/2008
Page 9 of 10
18.
Forecasts, models, analyses, evaluations, and projections concerning sales
of Prevacid ODT®, Teva's ODT Products or lansoprazole orally-dissolving tablets (15 and 30 mg) in the United States. 19. Information and documents relied on or reviewed by the 30(b)(6)
corporate representative(s), and the identities of any persons consulted by the corporate representative(s) for purposes of becoming knowledgeable about the topics set forth in this Notice, identified with topic-by-topic particularity. 20. The preparation of Teva's responses to Plaintiffs' Interrogatories and
Requests to Admit, and Teva's efforts to collect and produce documents pursuant to Plaintiffs' Requests for the Production of Documents and Things, and Teva's document retention policies from January 2001 to the present. 21. All facts concerning Teva's defenses in this case, including but not limited
to the defenses in its proposed Amended Answer to Plaintiffs' Complaint. 22. topics set forth above. The identities of the person(s) most knowledgeable about each of the
-6-
Case 1:07-cv-00331-SLR
Document 50
Filed 03/27/2008
Page 10 of 10
CERTIFICATE OF SERVICE I hereby certify that on March 27, 2008, I caused the foregoing to be electronically filed with the Clerk of the Court using CM/ECF which will send electronic notification of such filing to the following: Karen L. Pascale, Esquire Karen E. Keller, Esquire YOUNG CONAWAY STARGATT & TAYLOR, LLP
Additionally, I hereby certify that true and correct copies of the foregoing were caused to be served on March 27, 2008 upon the following individuals in the manner indicated: BY E-MAIL AND HAND DELIVERY Karen L. Pascale, Esquire YOUNG CONAWAY STARGATT & TAYLOR, LLP The Brandywine Building 1000 West Street, 17th Floor Wilmington, DE 19801 [email protected] BY E-MAIL John L. North, Esquire SUTHERLAND ASBILL & BRENNAN LLP [email protected] Jeffrey J. Toney, Esquire SUTHERLAND ASBILL & BRENNAN LLP [email protected] Laura Fahey Fritts, Esquire SUTHERLAND ASBILL & BRENNAN LLP [email protected] Jeffrey D. Blake SUTHERLAND ASBILL & BRENNAN LLP [email protected]
/s/ James W. Parrett, Jr.
______________________________________ James W. Parrett, Jr. (#4292)
1255493